|
- Treatment of acute kidney injury with cast nephropathy
Nearly 50% of patients with multiple myeloma develop renal disease; acute kidney injury (AKI) from cast nephropathy, or "myeloma kidney" is the most common type Development of AKI is associated with worse 1-year survival and reduces the therapeutic options available to patients Therefore, there is …
- Acute Kidney Injury: Diagnosis and Management | AAFP
Stage 3 acute kidney injury requiring renal replacement therapy is associated with mortality rates between 44% and 52% 44, 45 Observational studies have shown an increased risk of developing
- Treatment of multiple myeloma with renal involvement: the nephrologist . . .
In fact, as many as 10% of patients with MM develop dialysis-dependent acute kidney injury related to increased free light chain (FLC) production by a plasma cell clone Myeloma cast nephropathy (MCN) is the most prevalent pathologic diagnosis associated with renal injury, followed by light chain deposition disease and light chain amyloidosis
- Supportive therapy for cast nephropathy - Kidney International
The paper by Bridoux et al 1 addresses the management of acute kidney injury in multiple myeloma Early chemotherapy is considered priority intervention and high cutoff hemodialysis membranes a useful strategy to remove light chains (LCs), although no definitive results about its efficacy are yet available
- Kidney disease in multiple myeloma and other monoclonal . . . - UpToDate
Kidney injury most often occurs in patients with a high tumor burden and can evolve as either an acute or chronic disorder This topic will review the treatment of kidney disease in patients with multiple myeloma or other monoclonal gammopathies, with a focus on light chain cast nephropathy
- Light Chain-Associated Kidney Disease Treatment Management - Medscape
A randomized trial by Clarke et al in patients with acute kidney injury at the onset of multiple myeloma found that plasma exchange did not significant affect outcomes; however, this trial had several limitations, as there was substantial uncertainty regarding the diagnosis of cast nephropathy because only 61% of the patients had light chains
- Treating myeloma cast nephropathy without treating myeloma
Treatment of cast nephropathy by targeting THP and FLC interaction (A) Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model J Clin Invest 2012; 122 (5):1777–1785 [PMC free article] [Google Scholar] 10 Leung N, Rajkumar SV Renal manifestations of plasma cell disorders
- Treatment of Myeloma Cast Nephropathy associated Acute Kidney Injury . . .
typical in cast nephropathy, while the bottom depicts the non-selective or predominantly albumin proteinuria of amyloidosis, monoclonal immunoglobulin deposition disease, and other unrelated entities List 1 – Kidney diseases in multiple myeloma classified by site of injury 90,91 Glomerular •Primary amyloidosis (AL or AH)
|
|
|